New Delhi, Jan. 30 -- Sun Pharma, India's largest drugmaker, is set to post its results for the third quarter of the fiscal year on Saturday. While brokerages anticipate steady domestic growth and marginal sequential growth in its US business, driven by its innovative drugs, margins may contract due to increased spending.

Analysts will also be seeking clarity on any potential impact from the US government's most favoured nation (MFN) pricing norms, as well as the company's plans after getting regulatory approval to market semaglutide as a weight-loss drug in India earlier this month.

Sun Pharma's overall sales are expected to grow 5% year-on-year, (down 1% sequentially), with US sales declining 4% sequantially to $478 million on account...